Recon: MHRA approves Novo’s Wegovy for heart risks; Merck says RSV antibody succeeds in Phase 2b/3 study
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited States